Welcome to our dedicated page for Xcelerate news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on Xcelerate stock.
Xcelerate, Inc. (XCRT) publishes frequent updates on its progress in medical technology, AI-assisted virtual health and consumer health and beauty products. The news flow provides insight into how the company is executing its business plan, adjusting its portfolio of assets and advancing its intellectual property.
Recent press releases describe Xcelerate’s decision to sell its majority interest in the ESN Group of companies in an all-cash transaction to Noble Labs Holdings, LLC, with the stated goal of refocusing on its original mission of implementing AI-aided medical technology and virtual health care in Africa through its majority-owned subsidiary, AfiyaSasa Africa, LLC. Other announcements highlight renewed emphasis on the AfiyaSasa project, including plans to launch an AI-assisted patient portal in Tanzania and to acquire a clinical care setting in which the technology can be trialed, tested and applied.
News items also cover developments in Xcelerate’s medical device patents, such as the commencement of the nationalization process for PCT international patent applications related to a Surgical Tool with Targeting Guidance that introduces a "first-person view" to the surgical theatre. Additional releases discuss corporate matters, including changes of auditors, re-audits of financial statements, filings of annual and semi-annual reports, amendments to registration statements, and the engagement of an investment bank to assist with capital raising and potential up-listing to a national exchange.
Investors and observers can use the XCRT news feed on this page to follow company statements on AI-driven healthcare initiatives, patent filings, divestitures, funding arrangements and shareholder communications, all in one place.
Xcelerate, a leader in early-stage medical technology, announced on May 3, 2021, the removal of the 'Yield' sign from its stock symbol by OTC Markets, achieving 'Pink Current Reporting' status. This change enhances corporate transparency and allows investors better access to company information. CEO Michael O'Shea expressed enthusiasm for this milestone, emphasizing ongoing efforts to maintain compliance and improve corporate standing. Additionally, the company is exploring innovative acquisitions in the patent and engineering sectors to further its growth.
Xcelerate, Inc. (OTC: XCRT) has launched a new website, www.xcelerate.global, highlighting its innovative role in integrating advanced engineering solutions with MedTech and clinical care. The website aims to communicate the company's mission, progress, and potential within the MedTech sector, serving as a platform for updates and news. CEO Michael O'Shea emphasized that the global domain reflects the company’s aspirations for international growth and collaboration. Xcelerate focuses on acquiring patents and engineering technologies and is committed to advancing early-stage medical technologies.
Xcelerate, Inc. (OTC: XCRT) announced on April 27, 2021, that Vincent C. du Vigneaud has joined its Advisory Board. With over 25 years of experience in financial analysis and capital structure, du Vigneaud is currently the Head of Non-Standard Investments at FinTrust Capital Advisors, which manages over $1.5 billion. His expertise in regulatory issues and business combinations is expected to support Xcelerate's development plans. The company aims to innovate acquisitions in medical technology and enhance clinical applications.
Xcelerate has announced a new ticker symbol, XCRT, following its name change from Union Dental Holdings. CEO Michael O'Shea stated that this step enhances the company's identity. The company is exploring acquisitions in the medtech sector to innovate clinical care but has not yet secured agreements. Notable additions to its advisory board include Nobel Laureate Dr. Barry Marshall and renowned neurosurgeon Dr. Dilan Ellegala, which may bolster Xcelerate's credibility in the medical field.